# A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

> **NCT07783425** · PHASE3 · RECRUITING · sponsor: **Pfizer** · enrollment: 1375 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Tilrekimig
- **DRUG:** Dupilumab
- **OTHER:** Placebo for Tilrekimig
- **OTHER:** Placebo for Dupilumab

## Key facts

- **NCT ID:** NCT07783425
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-24
- **Primary completion:** 2028-09-08
- **Final completion:** 2029-06-15
- **Target enrollment:** 1375 (ESTIMATED)
- **Last updated:** 2026-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07783425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07783425, "A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema". Retrieved via MORVS 2026-11-22 from https://api.morvs.ai/clinical/NCT07783425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*
